Biotech Stock Valuations and Public Policy: Will “Buy” Ratings Make “21st Century Cures” A Tough Sell?
This article was originally published in RPM Report
Executive Summary
Wall Street remains enthusiastic about the prospects for biotechnology firms, with share prices up again to start 2015 after another year of big gains in 2014. But will all the “buy” ratings make it harder for the biopharma industry to sell Congress on the need for pro-innovation reforms?